Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03715452
Other study ID # TP-6579
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2017
Est. completion date March 30, 2018

Study information

Verified date October 2020
Source Osprey Medical, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective, single arm, multi-center, observational clinical study of the DyeVert Plus System. The DyeVert Plus System is an FDA-cleared device designed to reduce contrast media volume delivered during angiography and permit real-time contrast media volume monitoring.


Description:

The purpose of this observational study is to evaluate the amount of contrast media saved using DyeVert Plus in coronary angiographic and/or interventional procedures performed with manual injection and evaluate the impact of predetermined thresholds and real-time monitoring.


Recruitment information / eligibility

Status Completed
Enrollment 114
Est. completion date March 30, 2018
Est. primary completion date January 31, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Scheduled to undergo CAG and/or PCI - Baseline estimated glomerular filtration rate (eGFR) of =20 and =60 mL/ min/1.73 m2 Exclusion Criteria: - Acute ST-elevation myocardial infarction or known coronary artery fistulas - Body mass index (BMI) >40 - Currently pregnant - Undergoing a chronic total occlusion procedure or optical coherence tomography analysis - Planning to undergo transcatheter aortic valve replacement within 72 hr of the index procedure - A condition known to require large volumes of contrast (>10 mL) for each injection

Study Design


Intervention

Device:
DyeVert Plus Contrast Reduction System
The DyeVert Plus System interfaces with standard manifold systems to provide real-time contrast monitoring and reduce the amount of contrast used in catheterization procedures while maintaining fluoroscopic image quality. System components include a disposable, single-use, sterile DyeVert Plus Disposable Kit that contains a Smart Syringe and DyeVert Plus Module, which is connected to a standard manifold and provides fluid pathway resistance modulation via a dedicated diversion valve. The diversion valve self-adjusts to the manual injection pressure to divert some of the contrast media into the reservoir chamber within the module. This diverted volume of contrast media does not enter the patient.

Locations

Country Name City State
United States Atlanta VA Medical Center, Emory University School of Medicine Atlanta Georgia
United States University of Chicago Medical Center Chicago Illinois
United States Christ Hospital, Heart and Vascular Center, Lindner Research Center Cincinnati Ohio
United States WakeMed Heart and Vascular Raleigh North Carolina
United States William Beaumont Hospital Royal Oak Michigan
United States Washington University School of Medicine Saint Louis Missouri
United States Harbor UCLA Medical Center Torrance California
United States North Mississippi Medical Center Tupelo Mississippi

Sponsors (1)

Lead Sponsor Collaborator
Osprey Medical, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Contrast Media Volume Saved The percentage of contrast media volume saved (diverted) over the total procedure as reported on the DyeVert Plus display at the end of each case. At the time of the coronary angiography (CAG) or percutaneous coronary interventional (PCI) procedure
Secondary Evaluation of Adverse Events Through Discharge (From the Index Procedure) An adverse event is defined as "any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the medical device." DyeVert Plus System-related adverse events will be collected. Additionally, contrast media-related adverse events, such as acute kidney injury and anaphylactic shock, will be collected. From the time of the procedure through discharge (from the index procedure, approximately 0 - 3 days)
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4